PHILADELPHIA and VANCOUVER, British Columbia — January 15, 2026 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) has announced the closing of its best-efforts public offering of 5,366,726 units, generating gross proceeds of approximately US$30 million before deducting fees and expenses. The offering, detailed in a registration statement filed with the SEC, was made available on January 13, 2026.
Each unit comprised one common share or a pre-funded warrant and one warrant, priced at US$5.59 per unit, inclusive of the Pre-Funded Warrant exercise price. The warrants, trading on the Nasdaq Capital Market under the symbol “BCTXL” since January 14, 2026, allow the holder to purchase one common share at an exercise price of US$6.93 per share, expiring five years from the issuance date.
BriaCell relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.
The company plans to allocate the net proceeds to working capital, general corporate purposes, and the advancement of its business objectives.
ThinkEquity served as the sole placement agent for the offering.
The registration statement on Form S-1 (File No. 333-292388) related to the securities was filed with the Securities and Exchange Commission (“SEC”) on December 23, 2025, and became effective on January 13, 2026, and a related registration statement was filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, on January 13, 2026. Copies of the final prospectus are available from ThinkEquity in New York, and on the SEC’s website.
BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer care. More information is available at https://briacell.com/.
Contact Information:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
Source: BriaCell
